Scarica l'app Stockscreener
0.055
0.00%
0.00
Precedente Chiudi:
$0.055
Aprire:
$0.055
Volume 24 ore:
7,174
Relative Volume:
0.21
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
$-8.28M
Rapporto P/E:
-0.0235
EPS:
-2.3417
Flusso di cassa netto:
$-3.40M
1 W Prestazione:
+10.00%
1M Prestazione:
+37.50%
6M Prestazione:
-0.36%
1 anno Prestazione:
-99.85%
Intervallo 1D:
$0.055
$0.0595
Intervallo di 1 settimana:
$0.055
$0.0595
Portata 52W:
$0.0341
$0.10
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
Nome
Hepion Pharmaceuticals Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare HEPA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HEPA
Hepion Pharmaceuticals Inc
|
0.055 | 0 | 0 | -8.28M | -3.40M | -2.3417 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 110.47B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.67B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.53B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 43.81B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.36B | 606.42M | -1.28B | -997.58M | -6.403 |
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-07-20 | Ripresa | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc Borsa (HEPA) Ultime notizie
Analyst Calls: Does SKLZ stock benefit from AI growth2026 EndofYear Setup & Growth Focused Investment Plans - baoquankhu1.vn
MusclePharm (OTCMKTS:MSLP) & Hepion Pharmaceuticals (NASDAQ:HEPA) Critical Contrast - Defense World
Hepion Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript - GuruFocus
HEPA (Hepion Pharmaceuticals) Non Operating Income : $-4.49 Mil (TTM As of Dec. 2025) - GuruFocus
HEPA (Hepion Pharmaceuticals) 3-Year Share Buyback Ratio : -434.70% (As of Dec. 2025) - GuruFocus
Value Recap: What are analysts price targets for Hepion Pharmaceuticals Inc2026 Pullback Review & Stock Timing and Entry Methods - baoquankhu1.vn
Is Hepion Pharmaceuticals Inc stock good for income investors2026 Trade Ideas & Stepwise Trade Execution Plans - baoquankhu1.vn
Hepion Pharmaceuticals Inc (HEPA) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
S P Trends: Can Hepion Pharmaceuticals Inc be the next market leader2026 Setups & Verified Entry Point Detection - baoquankhu1.vn
Hepion Pharmaceuticals CEO Resigns and Interim CEO Appointed – Official SEC Filing March 2026 - Minichart
Hepion Pharmaceuticals (NASDAQ: HEPA) CEO Gary Stetz submits Form 3 - Stock Titan
Hepion Pharmaceuticals (OTC: HEPA) CEO exits as board installs new leaders - stocktitan.net
Bearish Setup: How sensitive is Hepion Pharmaceuticals Inc to inflationTrade Exit Summary & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Hepion Pharmaceuticals Stock (ISIN: US4268971032) Faces Uncertainty Amid Pipeline Delays and Biotech - AD HOC NEWS
Hepion (HEPA) exits liver drug program, pivots to diagnostics as cash window narrows - Stock Titan
HEPA: Net loss narrowed to $8.3M in 2025 as operations shifted to diagnostics, but no revenue was generated - TradingView
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Hepion Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
HEPA (Hepion Pharmaceuticals) NonCurrent Deferred Revenue : $0.00 Mil (As of Sep. 2025) - GuruFocus
Gap Down: Should I buy Hepion Pharmaceuticals Inc. stock now2026 Earnings Impact & Daily Momentum Trading Reports - baoquankhu1.vn
Hepion Expands Liver Cancer Liquid Biopsy Theranostics Portfolio - TipRanks
Hepion Pharmaceuticals (HEPA) Enhances Early Cancer Detection wi - GuruFocus
ctRNA deal advances Hepion (OTCQB: HEPA) liquid biopsy strategy - Stock Titan
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to - GlobeNewswire
HEPA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fundamentals Check: Will Hepion Pharmaceuticals Inc benefit from rate cuts2025 Performance Recap & Consistent Growth Equity Picks - baoquankhu1.vn
Can Hepion Pharmaceuticals Inc. scale operations efficientlyEarnings Overview Report & Long-Term Investment Growth Plans - mfd.ru
How strong is Hepion Pharmaceuticals Inc. stock balance sheet2025 Trading Recap & Verified Entry Point Signals - mfd.ru
What catalysts could drive Hepion Pharmaceuticals Inc. stock higherTrend Reversal & Real-Time Stock Entry Alerts - mfd.ru
Financial Review: Virios Therapeutics (NASDAQ:VIRI) versus Hepion Pharmaceuticals (NASDAQ:HEPA) - Defense World
Analyst Calls: Can Hepion Pharmaceuticals Inc scale operations efficiently2025 Price Momentum & Verified High Yield Trade Plans - baoquankhu1.vn
Can Hepion Pharmaceuticals Inc deliver consistent EPS growthJuly 2025 Weekly Recap & Daily Entry Point Alerts - baoquankhu1.vn
Aug Setups: How volatile is IQVIA Holdings Inc stockJuly 2025 Setups & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Market Catalysts: Is SPX Technologies Inc a turnaround storyPortfolio Update Summary & Real-Time Volume Triggers - baoquankhu1.vn
Bearish Setup: Is Bright Horizons Family Solutions Inc stock technically oversoldWeekly Trend Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Will Hepion Pharmaceuticals Inc. stock see PE expansionTrend Following Strategies & Free Unlock Stock Analysis - Bollywood Helpline
Weekly Recap: Will Interactive Strength Inc be affected by tariffs2025 Analyst Calls & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Aug Fed Impact: Can Hepion Pharmaceuticals Inc be the next market leader2025 Growth vs Value & Weekly Top Gainers Alerts - baoquankhu1.vn
Hepion Pharmaceuticals appoints Dr. Kaouthar Lbiati as CEO with new employment agreement - Investing.com Canada
Hepion Pharmaceuticals appoints Dr. Kaouthar Lbiati as CEO with new employment agreement By Investing.com - Investing.com South Africa
Market Review: Why Hepion Pharmaceuticals Inc stock could see breakout soonFed Meeting & Low Risk Entry Point Tips - Bộ Nội Vụ
Why Hepion Pharmaceuticals Inc stock remains resilientEarnings Growth Report & Real-Time Volume Surge Alerts - Bộ Nội Vụ
Why Hepion Pharmaceuticals Inc. (336) stock attracts wealthy investors2025 Price Targets & Risk Controlled Daily Trade Plans - ulpravda.ru
Aug Intraday: How Hepion Pharmaceuticals Inc. stock compares to growth peersJuly 2025 Trends & Weekly High Return Stock Forecasts - Улправда
Head to Head Analysis: Hepion Pharmaceuticals (NASDAQ:HEPA) versus eFFECTOR Therapeutics (NASDAQ:EFTR) - Defense World
Why Hepion Pharmaceuticals Inc. stock remains resilient2025 Performance Recap & Stepwise Trade Signal Implementation - ulpravda.ru
Is Hepion Pharmaceuticals Inc. stock a buy before product launchesMarket Performance Recap & Fast Entry and Exit Trade Plans - Улправда
Why Hepion Pharmaceuticals Inc. stock could see breakout soonGDP Growth & Stock Market Timing Techniques - ulpravda.ru
Is Hepion Pharmaceuticals Inc. (336) stock attractive post correctionInflation Watch & Smart Allocation Stock Tips - Улправда
How buybacks impact Hepion Pharmaceuticals Inc. stock valueWeekly Gains Report & Free Community Supported Trade Ideas - ulpravda.ru
Will Hepion Pharmaceuticals Inc. stock split attract more investorsQuarterly Portfolio Report & Long-Term Growth Stock Strategies - Улправда
Hepion Pharmaceuticals Inc Azioni (HEPA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.11%
Capitalizzazione:
|
Volume (24 ore):